Trial Profile
Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2016
Price :
$35
*
At a glance
- Drugs Unoprostone (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; Therapeutic Use
- Sponsors R-Tech Ueno Ltd
- 24 May 2016 New trial record